P. Neven

发表

A Mathematical Model for Interpretable Clinical Decision Support with Applications in Gynecology

Stephen P. Boyd, J. Suykens, T. Bourne, 2012, PloS one.

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

P. Neven, V. Semiglazov, S. Johnston, 2008, Breast Cancer Research and Treatment.

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

M. Beckmann, P. Fasching, R. Altman, 2013, Clinical pharmacology and therapeutics.

Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy.

E. van Limbergen, P. Neven, S. Peeters, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Parent-of-origin specific allelic associations among 106 genomic loci for age at menarche

Andrew D. Johnson, Daniel L. Koller, E. Demerath, 2014, Nature.

Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.

E. van Limbergen, P. Neven, M. Christiaens, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Kristen S Purrington, Jack A. Taylor, A. Whittemore, 2018, American Journal of Human Genetics.

A unifying model to predict variable drug response for personalised medicine

R. Vossen, S. Anvar, P. Neven, 2020, bioRxiv.

Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent

A. Whittemore, S. Cross, M. Beckmann, 2016, PLoS medicine.

Association analysis identifies 65 new breast cancer risk loci

Gary D Bader, Jaana M. Hartikainen, Jeffery M. Meyer, 2017, Nature.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jaana M. Hartikainen, W. Chung, 2019, Nature Genetics.

Nature Genetics Advance Online Publication Large-scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility and Brca1-mediated Dna Repair

Andrew D. Johnson, Samuel E. Jones, E. Demerath, 2022 .

Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair

Andrew D. Johnson, Samuel E. Jones, E. Demerath, 2015, Nature Genetics.

Prognostic implications of lobular breast cancer histology: new insights from a single hospital cross-sectional study and SEER data.

P. Neven, M. Christiaens, H. Wildiers, 2014, Breast.

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients

P. Neven, D. Lambrechts, R. Paridaens, 2015, Breast Cancer Research and Treatment.

A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

Jeffery M. Meyer, Richard T. Barfield, Jack A. Taylor, 2018, Nature Genetics.

Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs

B. Moor, C. Sotiriou, P. Neven, 2011, Breast Cancer Research and Treatment.

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

P. Neven, S. Loi, M. Piccart, 2022, European journal of cancer.

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

P. Neven, A. Goldhirsch, G. Viale, 2020, Clinical Cancer Research.

Clinicopathological Features of Inflammatory versus Noninflammatory Locally Advanced Nonmetastatic Breast Cancer

P. Neven, R. Paridaens, M. Christiaens, 2008, Tumor Biology.

Effect of cancer prevalence on the use of risk‐assessment cut‐off levels and the performance of mathematical models to distinguish malignant from benign adnexal masses

D. Jurkovic, T. Bourne, B. De Moor, 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

Patrick Neven, Sabine Van Huffel, Dirk Timmerman, 2007, Journal of the National Cancer Institute.

Management of borderline ovarian neoplasms.

P. Neven, F. Amant, T. Van Gorp, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The management of borderline tumours of the ovary

P. Neven, F. Amant, T. Van Gorp, 2006, Current opinion in oncology.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Patrick Neven, István Láng, A. Giobbie-Hurder, 2011, The Lancet. Oncology.

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

P. Fasching, P. Neven, F. Esteva, 2020, Breast.

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

P. Neven, S. Simoens, I. Huys, 2019, British Journal of Cancer.

The oestrogen receptor and its selective modulators in gynaecological and breast cancer.

P. Neven, I. Vergote, P. van Dam, 2000, European journal of cancer.

Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial.

P. Neven, A. Smeets, I. Nevelsteen, 2018, Archives of physical medicine and rehabilitation.

The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.

P. Neven, I. Vergote, F. Amant, 2013, Gynecologic oncology.

The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.

P. Neven, F. Amant, T. Van Gorp, 2007, Gynecologic oncology.

Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer

P. Neven, H. Wildiers, M. Regan, 2021 .

Endometrial Surveillance of Tamoxifen Patients

P. Neven, 2003 .

Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring.

P. Neven, F. Renard, D. Hertens, 2002, European journal of obstetrics, gynecology, and reproductive biology.

Tamoxifen, screening and new oestrogen receptor modulators.

P. Neven, I. Vergote, 2001, Best practice & research. Clinical obstetrics & gynaecology.

Guidelines for Monitoring Patients Taking Tamoxifen Treatment

P. Neven, Hilde Vernaeve, 2000, Drug safety.

Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

P. Neven, H. Ditzel, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

P. Neven, R. Gelber, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

P. Neven, R. Gelber, H. Ditzel, 2012, Journal of the National Cancer Institute.

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

J. Bergh, P. Neven, J. Crown, 2021, Breast cancer research : BCR.

The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

P. Carmeliet, P. Neven, B. de Strooper, 2014, EMBO Molecular Medicine.

Effect of myofascial techniques for treatment of persistent arm pain after breast cancer treatment: randomized controlled trial

P. Neven, M. Christiaens, M. Van Kampen, 2018, Clinical rehabilitation.

Myofascial techniques have no additional beneficial effects to a standard physical therapy programme for upper limb pain after breast cancer surgery: a randomized controlled trial

P. Neven, M. Christiaens, M. Van Kampen, 2017, Clinical rehabilitation.

Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant

D. Timmerman, P. Neven, R. Paridaens, 2009, Breast Cancer Research and Treatment.

Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.

D. Timmerman, P. Neven, S. Van Huffel, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Advances in the treatment of oestrogen receptor positive advanced breast cancer

P. Neven, S. Loibl, F. André, 2017 .

Lifestyle changes and breast cancer prognosis: a review

P. Neven, E. Kellen, M. Christiaens, 2009, Breast Cancer Research and Treatment.

A Systematic Review of Estimating Breast Cancer Recurrence at the Population-Level with Administrative Data.

P. Neven, H. Wildiers, I. Vergote, 2020, Journal of the National Cancer Institute.

Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole

B. van Calster, D. Timmerman, P. Neven, 2010, Menopause.

Association between CYP2D6 polymorphisms and breast cancer outcomes.

V. Van Belle, P. Neven, A. Dieudonné, 2010, JAMA.

Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence

P. Neven, R. Paridaens, H. Wildiers, 2009, Breast Cancer Research and Treatment.

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

E. van Limbergen, P. Neven, R. Paridaens, 2005, Journal of Clinical Pathology.

Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing.

P. Neven, J. Vermeesch, L. Dehaspe, 2015, JAMA oncology.

Breast cancer subtype and survival by parity and time since last birth

E. van Limbergen, P. Neven, H. Wildiers, 2018, Breast Cancer Research and Treatment.

Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity

F. Bertucci, P. Neven, P. V. van Dam, 2020, Breast Cancer Research and Treatment.

Tamoxifen and the gynaecologist

P. Neven, D. Lowe, J. Shepherd, 1993, British journal of obstetrics and gynaecology.

A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

P. Neven, P. Benedetti‐Panici, T. Nickelsen, 2003, BJOG : an international journal of obstetrics and gynaecology.

A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis

P. Neven, T. Van Gorp, K. Deraedt, 2008, Breast Cancer Research.

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.

P. Neven, I. Vergote, F. Amant, 2005, Gynecologic oncology.

Quality of pathology reporting is crucial for cancer care and registration: a baseline assessment for breast cancers diagnosed in Belgium in 2008.

P. Neven, C. Colpaert, A. Cornelis, 2015, Breast.

Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21

S. Cross, P. Fasching, A. Børresen-Dale, 2016, Oncotarget.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.

A. Giobbie-Hurder, P. Neven, A. Goldhirsch, 2009 .

Local levonorgestrel to prevent tamoxifen-related endometrial lesions

P. Neven, 2000, The Lancet.

Breast cancer in pregnancy: recommendations of an international consensus meeting.

L. Lagae, P. Neven, R. Rouzier, 2010, European journal of cancer.

S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis

A. LaCroix, S. Cummings, T. Powles, 2009 .

0033 Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels

A. LaCroix, S. Cummings, T. Powles, 2009 .

Behavior of metastatic breast cancer according to subtype

P. Neven, H. Wildiers, G. Floris, 2020, Breast Cancer Research and Treatment.

Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium.

T. Bourne, P. Neven, D. Phillips, 1999, Carcinogenesis.

Should tamoxifen users be screened for endometrial lesions?

P. Neven, I. Vergote, 1998, The Lancet.

Tamoxifen and the uterus

P. Neven, R. Campo, X. Muylder, 1994, European journal of cancer.

Tamoxifen and the female genital tract.

P. Neven, P. Carmichael, A. Ugwumadu, 1998, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

P. Neven, I. Vergote, V. Jordan, 1996, European journal of cancer.

Tamoxifen and the uterus.

P. Neven, R. Campo, Y. van Belle, 1998, BMJ.

Tamoxifen and endometrial lesions

P. Neven, 1993, The Lancet.

An unusual type of endometrial cancer, related to tamoxifen?

P. Neven, J. Deprest, P. Ide, 1992, European journal of obstetrics, gynecology, and reproductive biology.

Endometrial lesions in patients undergoing tamoxifen therapy

P. Neven, Y. van Belle, X. De Muylder, 1991, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Hysteroscopic follow-up during tamoxifen treatment.

P. Neven, Y. van Belle, X. De Muylder, 1990, European journal of obstetrics, gynecology, and reproductive biology.

Tamoxifen and the uterus and endometrium.

P. Neven, Y. van Belle, X. De Muylder, 1989, Lancet.

TAMOXIFEN AND THE UTERUS AND ENDOMETRIUM

P. Neven, M. Tortajada, F. Bonilla-musoles, 1989, The Lancet.

Endometrial safety of hormone replacement therapy: review of literature.

P. Neven, T. Van Gorp, T. van Gorp, 2002, Maturitas.

Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.

P. Neven, H. Depypere, T. Nickelsen, 2005, Maturitas.

Controversies regarding tamoxifen and uterine carcinoma.

P. Neven, I. Vergote, 1998, Current Opinion in Obstetrics and Gynecology.

Sentinel lymph node involvement in ductal carcinoma in-situ of the breast: two different causes.

P. Neven, R. Paridaens, M. Christiaens, 2012, Clinical breast cancer.

Breast cancer in pregnancy

P. Neven, S. Loibl, F. Amant, 2012, The Lancet.

Malignancies in Pregnancy 2 Breast cancer in pregnancy

P. Neven, S. Loibl, F. Amant, 2012 .

Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study.

P. Neven, M. Christiaens, N. Gebruers, 2016, Breast.

Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?

E. van Limbergen, N. Pochet, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Physical activity levels after treatment for breast cancer: one-year follow-up

P. Neven, J. Lefevre, M. Christiaens, 2010, Breast Cancer Research and Treatment.

Safety of aromatase inhibitor therapy in breast cancer

P. Neven, A. Lintermans, 2015, Expert opinion on drug safety.

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer

P. Neven, D. Lambrechts, H. Guchelaar, 2020, Cancer Chemotherapy and Pharmacology.

Does patient education work in breast cancer? Final results from the global CARIATIDE study.

S. Barni, P. Neven, R. Kreienberg, 2015, Future oncology.

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

J. Forbes, P. Neven, C. Barrios, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.

P. Neven, G. Jerusalem, O. Paija, 2012, Clinical breast cancer.

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

P. Neven, G. von Minckwitz, A. Monnier, 2008, Cancer.

Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study

P. Neven, R. Paridaens, M. Christiaens, 2008, Breast Cancer Research and Treatment.

Age‐dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients

P. Neven, R. Peeters, S. Sunaert, 2019, Human brain mapping.

Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome.

P. Neven, F. Amant, T. Van Gorp, 2007, American journal of obstetrics and gynecology.

Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients

E. van Limbergen, P. Neven, F. Amant, 2002, International Journal of Gynecologic Cancer.

NCOLOGY aparoscopy-assisted vaginal hysterectomy compared with bdominal hysterectomy in clinical stage I endometrial ancer : safety , recurrence , and long-term outcome

P. Neven, F. Amant, I. Vergote, 2022 .

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

P. Neven, D. Lambrechts, F. Amant, 2015, BMC Pharmacology and Toxicology.

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters

P. Neven, H. Wildiers, G. Pawelec, 2016, Oncotarget.

Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up.

J. Menten, B. van Calster, P. Neven, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines

D. Timmerman, P. Neven, H. Wildiers, 2020, Journal of oncology.

Detection and diagnosis

P. Neven, C. Denkert, M. Dietel, 2012 .

Coping with menopausal symptoms: An internet survey of Belgian postmenopausal women.

P. Neven, H. Depypere, A. Pintiaux, 2015, Maturitas.

Endometriosis and the development of malignant tumours of the pelvis. A review of literature.

P. Neven, I. Vergote, F. Amant, 2004, Best practice & research. Clinical obstetrics & gynaecology.

Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study.

P. Neven, H. Wildiers, A. Smeets, 2022, Clinical Breast Cancer.

The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers.

P. Neven, M. Christiaens, H. Wildiers, 2013, Breast.

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

P. Neven, R. Steele, A. Vincent-Salomon, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Uterine ultrasound and endometrial biopsy in tamoxifen users

D. Timmerman, P. Neven, W. Froyman, 2020, Breast Cancer Research and Treatment.

Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.

D. Timmerman, P. Neven, P. Cin, 1998, Cancer research.

Lack of genotoxicity of tamoxifen in human endometrium.

P. Neven, D. Phillips, A. Hewer, 1996, Cancer research.

Chemotherapy for recurrent cervical cancer.

P. Neven, F. Amant, T. Van Gorp, 2007, Gynecologic oncology.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

P. Neven, A. Bardia, F. Bidard, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

P. Neven, F. Cardoso, L. Mauriac, 2010, Breast Cancer Research and Treatment.

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

C. Sotiriou, P. Neven, M. Ignatiadis, 2021, npj Breast Cancer.

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

P. Neven, H. Rugo, Yeon-Hee Park, 2021, The Lancet. Oncology.

Any questions: How long is it safe to take tamoxifen?

P. Neven, 1997 .

The Role of Inhibins B and Antimüllerian Hormone for Diagnosis and Follow-up of Granulosa Cell Tumors

P. Neven, J. Billen, I. Geerts, 2009, International Journal of Gynecologic Cancer.

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

P. Neven, M. Okada, N. Harbeck, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables

P. Neven, R. Paridaens, M. Christiaens, 2005, Clinical & Experimental Metastasis.

Drug safety evaluation of exemestane

P. Neven, R. Paridaens, A. Lintermans, 2011, Expert opinion on drug safety.

Title: Obesity alters endoxifen plasma levels in young breast cancer patients: A pharmacometric simulation approach. Authors:

W. Huisinga, P. Neven, H. Brauch, 2020 .

Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium

Alicja, Marike, Truong, 2020 .

The costs of breast cancer prior to and following diagnosis

P. Neven, S. Simoens, M. Christiaens, 2011, The European Journal of Health Economics.

Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors

P. Neven, F. Amant, P. Moerman, 2017, Gynecologic and Obstetric Investigation.

Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3

P. Neven, H. Wildiers, A. Smeets, 2021, ESMO open.

Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation

P. Neven, D. Hayes, Kelly Speth, 2017, Clinical breast cancer.

Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.

B. van Calster, D. Timmerman, P. Neven, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor

P. Neven, R. Paridaens, H. Wildiers, 2011, Menopause.

Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study

P. Neven, R. Paridaens, H. Wildiers, 2018, Breast Cancer Research and Treatment.

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

P. Neven, F. André, G. Jerusalem, 2014, Current medical research and opinion.

Breast cancer chemoprevention in the high-risk patient

P. Neven, Uz Leuven, 2008 .

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

P. Neven, R. Paridaens, M. Christiaens, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related

P. Neven, R. Paridaens, M. Christiaens, 2005, Breast Cancer Research and Treatment.

Uterine Effects of Estrogen Plus Progestin Therapy and Raloxifene: Adjudicated Results From the EURALOX Study

P. Neven, T. Nickelsen, C. De Geyter, 2004, Obstetrics and gynecology.

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women.

P. Neven, S. Silfen, D. Muram, 2002 .

RAPID COMMUNICATION The Effect of Raloxifene on the Incidence of Ovarian Cancer in Postmenopausal Women 1

P. Neven, S. Silfen, D. Muram, 2002 .

Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.

P. Neven, D. Lambrechts, D. Vanderschueren, 2016, European journal of cancer.

The origin of postmenopausal oestrogens.

P. Neven, 2002, European journal of cancer.

Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass

P. Neven, D. Cox, S. Dowsett, 2012, Menopause.

Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer

P. Neven, F. Amant, K. Leunen, 2016 .

Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer

P. Neven, K. Leunen, I. Vergote, 2016, International Journal of Gynecologic Cancer.

Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer

P. Neven, I. Kindts, A. Laenen, 2019, Breast.

Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines

P. Neven, H. Wildiers, M. Berlière, 2016 .

Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.

P. Neven, I. Vergote, F. Amant, 2008, The oncologist.

Hormonal interventions and cancer risk

P. Neven, X. Muylder, 1995, The Lancet.

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.

P. Neven, C. Desmedt, M. Piccart, 2022, Future oncology.

Port‐site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma

P. Neven, I. Vergote, F. Amant, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

P. Neven, M. Piccart, G. Hortobagyi, 2013, Cancer.

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

P. Neven, M. Campone, D. Hayes, 2016, Clinical Cancer Research.

Does the Stellate Ganglion Block Reduce Severe Hot Flushes and Sleep Disturbances in Breast Cancer Patients

J. Menten, P. Neven, R. Paridaens, 2009 .

elevated aerum markers in non invasive breast cancer five cases and review of literature introduction

P. Neven, M. Smet, Floris Giuseppe, 2017 .

A mindfulness-based intervention for breast cancer patients with cognitive impairment after chemotherapy: study protocol of a three-group randomized controlled trial

P. Neven, S. Sunaert, P. Kuppens, 2019, Trials.

Anastrozole and fulvestrant in metastatic breast cancer.

P. Neven, J. Vanderhaegen, A. Lintermans, 2012, The New England journal of medicine.

Managing the side effects of oral aromatase inhibitors

P. Neven, O. Brouckaert, A. Lintermans, 2012 .

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients

E. van Limbergen, D. Timmerman, P. Neven, 2004, Anti-cancer drugs.

Management of menopausal symptoms in breast cancer patients.

P. Neven, S. Loibl, A. Dieudonné, 2011, Maturitas.

Impact of a compression garment, on top of the usual care, in patients with breast cancer with early disturbance of the lymphatic transport: protocol of a randomised controlled trial

P. Neven, I. Nevelsteen, I. Fourneau, 2020, BMJ Open.

Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters?

P. Neven, A. Soubry, Stephanie Romanus, 2016, Breast Cancer Research.

Prophylactic salpingo-oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia

P. Neven, F. Amant, E. Legius, 2005, International Journal of Gynecologic Cancer.

A Real-Life Analysis of Reproductive Outcome after Fertility Preservation in Female Cancer Patients

P. Neven, H. Wildiers, F. Amant, 2017, Gynecologic and Obstetric Investigation.

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.

P. Neven, H. Guchelaar, S. Böhringer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial

B. van Calster, P. Neven, S. Van Huffel, 2018, Clinical Cancer Research.

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

H. Putter, P. Neven, H. Gelderblom, 2015, Breast Cancer Research and Treatment.

How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?

P. Neven, H. Wildiers, A. Dieudonné, 2014, Acta Clinica Belgica.

The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.

D. Timmerman, P. Neven, D. Lambrechts, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

S. Huffel, D. Timmerman, P. Neven, 2009, Breast Cancer Research and Treatment.

In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.

B. van Calster, V. Van Belle, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors

Patrick Neven, Daniel F. Schmidt, Julian Peto, 2013, PLoS genetics.

Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

Patrick Neven, Hui Zhao, Nazneen Rahman, 2012, PloS one.

Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

Daniel J. Park, S. Cross, M. Beckmann, 2012, PLoS ONE.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.

P. Fasching, P. Neven, S. Im, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Usefulness of urodynamic investigations in female incontinence.

P. Neven, X. De Muylder, H. Claes, 1992, European journal of obstetrics, gynecology, and reproductive biology.

Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

P. Neven, S. Loi, S. Loibl, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.

P. Neven, I. Vergote, F. Amant, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial

A. Giobbie-Hurder, P. Neven, R. Gelber, 2020, Cancer.

Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

A. Giobbie-Hurder, P. Neven, R. Gelber, 2020, Breast Cancer Research and Treatment.

Pharmacology of arthralgia with estrogen deprivation

P. Neven, A. Lintermans, 2011, Steroids.

Protocol of a randomised controlled trial regarding the effectiveness of fluoroscopy-guided manual lymph drainage for the treatment of breast cancer-related lymphoedema (EFforT-BCRL trial).

P. Neven, I. Nevelsteen, N. Gebruers, 2017, European journal of obstetrics, gynecology, and reproductive biology.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole

A. Giobbie-Hurder, P. Neven, B. Gusterson, 2008 .

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

B. van Calster, D. Timmerman, P. Neven, 2022, NPJ genomic medicine.

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

P. Fasching, P. Neven, F. Esteva, 2019, The New England journal of medicine.

Screening for neural tube defect with maternal serum a-fetoprotein and ultrasound without the use of amniocentesis

P. Neven, R. Geirsson, R. Smith, 1991 .

Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab

K. Nackaerts, P. Neven, H. Wildiers, 2018, Acta clinica Belgica.

Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

K. Nackaerts, P. Neven, H. Wildiers, 2018, Supportive Care in Cancer.

Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies

P. Neven, K. Devriendt, J. Vermeesch, 2021, EClinicalMedicine.

Improving outcome in the first-line management of advanced ovarian cancer

P. Neven, I. Vergote, F. Amant, 2007 .

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy

P. Neven, H. Wildiers, A. Smeets, 2022, Translational oncology.

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

P. Neven, H. Wildiers, G. Pawelec, 2017, Breast Cancer Research.

Laparoscopic hysterectomy for early endometrial cancer.

P. Neven, I. Vergote, F. Amant, 2010, The Lancet. Oncology.

The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer.

P. Neven, F. Amant, T. Van Gorp, 2007, Cancer treatment and research.

The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study

P. Neven, F. Amant, J. Trovik, 2010, International Journal of Gynecologic Cancer.

Lymphadenectomy in endometrial cancer : when

P. Neven, I. Vergote, F. Amant, 2010 .

Endometrial cancer: predictors of response and preferred endocrine therapy.

P. Neven, F. Amant, K. Leunen, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer.

P. Neven, F. Amant, D. Tsolakidis, 2010, Gynecologic oncology.

Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes

S. Cummings, P. Neven, T. Colgan, 2011, Menopause.

Laparoscopic para‐ aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2–IIIB

E. van Limbergen, P. Neven, F. Amant, 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Value of positron emission tomography of the para-aortic lymph nodes in cervical carcinoma stage IB2-IIIB.

E. van Limbergen, P. Neven, F. Mottaghy, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer

P. Neven, R. Paridaens, H. Wildiers, 2008, Breast Cancer Research and Treatment.

Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.

P. Neven, G. Sledge, H. Rugo, 2018 .

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.

P. Fasching, P. Neven, F. Esteva, 2018 .

Multivariate analysis of factors affecting survival in pelvic exenteration

P. Neven, H. Ngan, W. Hendry, 1994, International Journal of Gynecologic Cancer.

Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases.

P. Neven, F. Amant, P. Moerman, 2013, European journal of cancer.

Cognitions and physical impairments in relation to upper limb function in women with pain and myofascial dysfunctions in the late stage after breast cancer surgery: an exploratory cross-sectional study

P. Neven, A. Smeets, L. De Baets, 2021, Disability and rehabilitation.

Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.

B. van Calster, D. Timmerman, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

S. Huffel, P. Neven, V. Belle, 2009, Breast Cancer Research and Treatment.

Malignant melanoma of the vulva and vagina: a report of 23 cases presenting in a 10-year period

P. Neven, D. Lowe, J. Shepherd, 1993, International Journal of Gynecologic Cancer.

Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.

P. Neven, R. Paridaens, M. Christiaens, 2006, International Journal of Gynecological Cancer.

E12. Managing toxicity of aromatase inhibitors in early breast cancer

P. Neven, R. Paridaens, A. Lintermans, 2012 .

Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

P. Carmeliet, P. Neven, C. Desmedt, 2022, Nature Communications.

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

P. Neven, V. Tjan-Heijnen, I. Láng, 2020, Clinical and Translational Oncology.

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.

P. Neven, G. Hortobagyi, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-Term Prognostic Index for Breast Cancer: NPI or Lpi

S. Huffel, V. Van Belle, P. Neven, 2007, Pathology research international.

Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors.

P. Neven, D. Vanderschueren, J. Verhaeghe, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

D. Timmerman, P. Neven, R. Paridaens, 2007, Breast Cancer Research and Treatment.

The estrogen receptor has a prognostic value in progesterone receptor-positive breast cancer

B. Moor, N. Pochet, P. Neven, 2006 .

The influence of body composition and hormone replacement therapy (HRT) on progesterone receptor (PR) expression in postmenopausal women with an oestrogen receptor (ER)-positive breast cancer

B. Moor, N. Pochet, P. Neven, 2006 .

Abstract P5-11-01: The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up

P. Neven, H. Eidtmann, G. Minckwitz, 2010 .

Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST.

P. Neven, C. Barrios, A. Brufsky, 2009 .

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

P. Neven, G. Jerusalem, I. Deleu, 2007 .

Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al.

P. Neven, H. Guchelaar, S. Böhringer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.

P. Neven, R. Paridaens, M. Christiaens, 2014, European journal of cancer.

Sensitive routine liquid chromatography–tandem mass spectrometry method for serum estradiol and estrone without derivatization

P. Neven, F. Claessens, D. Vanderschueren, 2013, Analytical and Bioanalytical Chemistry.

Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort

J. Menten, P. Neven, H. Wildiers, 2021, Journal of Cancer Research and Clinical Oncology.

Longitudinal hysteroscopic follow-up during tamoxifen treatment

P. Neven, X. Muylder, Y. Belle, 1998, The Lancet.

11q13 is a susceptibility locus for hormone receptor positive breast cancer

Patrick Neven, Michael Jones, Michael Bremer, 2012, Human mutation.

P. Neven, G. Sledge, E. Grischke, 2020, The oncologist.

Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.

P. Neven, S. Pauwels, J. Billen, 2022, Clinical breast cancer.

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

P. Neven, G. Sledge, S. Johnston, 2021, Clinical Cancer Research.

Endocrine treatment and prevention of breast and gynaecological cancers

P. Neven, P. Dam, W. Tjalma, 2002 .

Tamoxifen therapy for patients with breast cancer

P. Neven, S. Linn, F. Cardoso, 2013, The Lancet.

False-negative tests in breast cancer management.

J. Menten, P. Neven, K. Leunen, 2011, The Netherlands journal of medicine.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

J. Cuzick, A. Howell, J. Forbes, 2016, The Lancet.

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

A. Schneeweiss, P. Neven, S. Loibl, 2021, European journal of cancer.

The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy: an Analysis of 74 Patients With Advanced Epithelial Ovarian Cancer

P. Neven, F. Amant, D. Tsolakidis, 2010, International Journal of Gynecologic Cancer.

Oestrogen and female cancers. the past 100 years.

P. Neven, 2000, European journal of cancer.

Scalp cooling in breast cancer patients treated with docetaxel–cyclophosphamide: patient- and nurse-reported results

P. Neven, H. Wildiers, E. Dejaeger, 2021, Breast Cancer Research and Treatment.

Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.

D. Timmerman, P. Neven, R. Paridaens, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

The prognostic and predictive value of the progesterone receptor in women with an oestrogen receptor positive breast cancer

P. Neven, R. Paridaens, M. Christiaens, 2004 .

Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?

P. Neven, F. Amant, E. Legius, 2009, International Journal of Gynecologic Cancer.

Postpartum breast cancer behaves differently

P. Neven, F. Amant, K. Van Calsteren, 2011, Facts, views & vision in ObGyn.

A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI

P. Neven, R. Paridaens, M. Christiaens, 2014, Breast Cancer Research and Treatment.

Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.

P. Neven, I. Vergote, F. Amant, 2012, Gynecologic oncology.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

P. Neven, K. Gelmon, H. Rugo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period

P. Neven, D. Lambrechts, M. Schmidt, 2021, Data in brief.

Juvenile Papillomatosis: A Case Report.

P. Neven, T. Langenaeken, M. Keupers, 2019, European journal of breast health.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm

P. Neven, R. Paridaens, H. Wildiers, 2016, Breast Cancer Research and Treatment.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

P. Neven, B. Naume, I. Láng, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of diaphragmatic surgery in 69 patients with ovarian carcinoma

P. Neven, F. Amant, T. Van Gorp, 2007, International Journal of Gynecologic Cancer.

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

B. van Calster, P. Neven, S. Van Huffel, 2007, British Journal of Cancer.

Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors

P. Neven, F. Amant, P. Moerman, 2016, International Journal of Gynecologic Cancer.

Retrospective Cohort Study of Practical Applications of Paramagnetic Seed Localisation in Breast Carcinoma and Other Malignancies

P. Neven, C. Van Ongeval, A. Smeets, 2022, Cancers.

Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.

P. Neven, D. Lambrechts, R. Paridaens, 2016 .

Combined modality adjuvant therapy for high-risk endometrial cancer.

P. Neven, I. Vergote, A. Vanderstichele, 2016, The Lancet. Oncology.

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

P. Neven, M. Campone, D. Hayes, 2014 .

Endometrial cancer.

Patrick Neven, Dirk Timmerman, Philippe Moerman, 2005, Lancet.

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.

Victoria L. Cafourek, S. Cross, M. Beckmann, 2011, Journal of the National Cancer Institute.

Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study

P. Neven, O. Ortmann, P. Grob, 2014, Breast Cancer Research and Treatment.

Quasiclassical approach to low-dimensional topological insulators and superconductors

P. Neven, 2015 .

Urinary chorionic gonadotropin subunits and β‐core in nonpregnant women. A study of benign and malignant gynecologic disorders

P. Neven, T. Chard, C. Hudson, 1993, Cancer.

Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance.

P. Neven, T. Chard, J. Shepherd, 1995, British Journal of Cancer.

The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix.

P. Neven, T. Chard, J. Shepherd, 1994, Gynecologic oncology.

Diurnal variation of urinary "hCG beta subunit core fragment" production evaluated in patients with gynecological neoplasms.

P. Neven, T. Chard, J. Shepherd, 1994, Clinical chemistry.

The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.

P. Neven, T. Chard, J. Shepherd, 1993, Gynecologic oncology.

Substantial urinary concentrations of material resembling beta-core fragment of chorionic gonadotropin beta-subunit in mid-menstrual cycle.

W. Collins, P. Neven, T. Chard, 1993, Clinical chemistry.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

P. Neven, M. Piccart, G. Hortobagyi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Diurnal VarIatIon of Urinary "hCG $ Subunit Core Fragment" Production Evaluated in Patients wfth

P. Neven, J. Shepherd, P. Carter, 1994 .

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

A. LaCroix, S. Cummings, T. Powles, 2010, Journal of the National Cancer Institute.

EP-EMA Regimen (Etoposide and Cisplatin With Etoposide, Methotrexate, and Dactinomycin) in a Series of 18 Women With Gestational Trophoblastic Neoplasia

P. Neven, F. Amant, Sileny N. Han, 2012, International Journal of Gynecologic Cancer.

Update on triple-negative breast cancer: prognosis and management strategies

P. Neven, H. Wildiers, G. Floris, 2012, International journal of women's health.

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

P. Neven, D. Lambrechts, R. Paridaens, 2014, Breast Cancer Research and Treatment.

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

P. Neven, D. Lambrechts, R. Paridaens, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

Patrick Neven, Päivi Heikkilä, Giu-Cheng Hsu, 2011, Human molecular genetics.

The genetic landscape of 87 ovarian germ cell tumors.

P. Neven, D. Lambrechts, I. Vergote, 2018, Gynecologic oncology.

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

Patrick Neven, Peter Kraft, Nazneen Rahman, 2015 .

Genome-wide association studies identify four ER negative–specific breast cancer risk loci

Patrick Neven, Michael Jones, Wei Lu, 2013, Nature Genetics.

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

A. Schneeweiss, P. Neven, C. Denkert, 2015, Breast Cancer Research and Treatment.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

G. Mills, R. Bernards, C. Sotiriou, 2016, Clinical Cancer Research.

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

R. Schiff, P. Neven, J. Mackey, 2011, Clinical Cancer Research.

P. Neven, G. Sledge, E. Grischke, 2019, The oncologist.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

P. Neven, G. Sledge, S. Johnston, 2019, JAMA oncology.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

P. Fasching, P. Neven, F. Esteva, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

P. Neven, G. Sledge, X. Pivot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

P. Fasching, P. Neven, C. Wang, 2022, Annals of Oncology.

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

P. Neven, D. Slamon, S. Chia, 2020 .

Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

P. Fasching, P. Neven, D. Slamon, 2021, Journal of Clinical Oncology.

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers

P. Neven, G. Floris, F. Amant, 2021, Scientific Reports.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial

P. Neven, M. Piccart, S. Tyekucheva, 2021 .

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

P. Neven, C. Desmedt, D. Lambrechts, 2021, Nature Medicine.

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

P. Neven, D. Rea, R. Rouzier, 2017, Breast.

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

M. Beckmann, P. Fasching, P. Neven, 2012, Breast Cancer Research and Treatment.

Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study

P. Neven, S. Chia, G. Jerusalem, 2019, Poster Discussion Abstracts.

Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

Jaana M. Hartikainen, S. Cross, M. Beckmann, 2014, Nature Communications.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.

Jaana M. Hartikainen, Kristen S Purrington, S. Cross, 2015, Carcinogenesis.

The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

Patrick Neven, Vito Michele Fazio, Sebastian Munck, 2013, EMBO molecular medicine.

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses

D. Timmerman, P. Neven, D. Lambrechts, 2016, Clinical Cancer Research.

Effects of tamoxifen on uterus

T. Bourne, W. Collins, S. Campbell, 1994, The Lancet.

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data

T. Speed, C. Sotiriou, P. Neven, 2014, Genome Biology.

Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer.

P. Neven, H. Wildiers, G. Floris, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer

P. Neven, S. Loibl, F. André, 2017, The Lancet.

Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates

G. Silversmit, P. Neven, H. Wildiers, 2021, Archives of Public Health.

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment.

I Vergote, P. Neven, D. Lambrechts, 2010, Gynecologic oncology.

Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization.

Jaana M. Hartikainen, A. Whittemore, S. Cross, 2015, Journal of the National Cancer Institute.

A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples

P. Neven, P. V. van Dam, G. G. Van den Eynden, 2014, PloS one.

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

T. Bourne, B. van Calster, D. Timmerman, 2022, npj Genomic Medicine.

Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer

P. Neven, F. Amant, K. Leunen, 2006, International Journal of Gynecologic Cancer.

Gemcitabine–carboplatin–paclitaxel combination as first‐line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

P. Neven, F. Amant, I. Vergote, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Triple negative breast cancer: clinical characteristics in the different histological subtypes.

B. van Calster, P. Neven, R. Paridaens, 2013, Breast.

Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

P. Neven, C. Desmedt, A. Salomon, 2020, Journal of the National Cancer Institute.

THE DIAGNOSTIC PROBLEM OF ENDOMETRIAL STROMAL SARCOMA: REPORT ON SIX CASES

P. Neven, F. Amant, P. Moerman, 2003, International Journal of Gynecologic Cancer.

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

C. Sotiriou, P. Neven, S. Loi, 2015, Oncotarget.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients.

P. Neven, F. Amant, D. Tsolakidis, 2011, European journal of cancer.

The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial

Patrick Neven, Benjamin Haibe-Kains, Christine Desmedt, 2009, BMC Medical Genomics.

Timing of debulking surgery in advanced ovarian cancer

I Vergote, K Leunen, P. Neven, 2008, International Journal of Gynecologic Cancer.

Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes

P. Neven, C. Desmedt, H. Wildiers, 2020, Breast Cancer Research and Treatment.

Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.

E. van Limbergen, P. Neven, P. Moerman, 2015, Gynecologic oncology.

Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.

T. Fehm, B. van Calster, P. Neven, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review

P. Neven, M. De Hert, A. Mitchell, 2016, Acta Psychiatrica Scandinavica.

Serum, Pleural Effusion, and Ascites CA-125 Levels in Ovarian Cancer and Nonovarian Benign and Malignant Diseases: A Comparative Study

P. Neven, S. Peacock, N. Urban, 2002 .

Endocrine treatment and prevention of breast and gynaecological cancers.

P. Neven, W. Tjalma, I. Vergote, 2004, European journal of cancer.

Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen‐treated women

D. Timmerman, P. Neven, I. Vergote, 2003, Cancer.

Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas

J. Decock, P. Neven, R. Paridaens, 2007, Disease markers.

The diagnostic problem of endometrial stromal sarcoma

P. Neven, F. Amant, P. Moerman, 2002 .

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy

P. Neven, A. Musolino, K. Blackwell, 2017, Breast Cancer Research.

Identiﬁcation and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk

S. Cross, M. Beckmann, P. Fasching, 2022 .

Identification and characterization of novel associations in the CASP 8 / ALS 2 CR 12 region on chromosome 2 with breast cancer risk

Halverson, Kristen S Purrington, M. Beckmann, 2014 .

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Everolimus plus exemestane in patients with advanced invasive lobular carcinoma: Efficacy and safety results from BOLERO-2.

P. Neven, F. Ringeisen, S. Noguchi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase Inhibitors in Premenopausal Women: The Need for Proper Contraceptive Counseling

P. Neven, R. Paridaens, M. Christiaens, 2006, The breast journal.

P. Neven, H. Wildiers, G. Floris, 2020, Clinical & translational immunology.

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.

P. Neven, D. Lambrechts, I. Vergote, 2022, Gynecologic oncology.

Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.

B. van Calster, D. Timmerman, P. Neven, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer

P. Neven, O. Ortmann, P. Grob, 2015, Climacteric : the journal of the International Menopause Society.

Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study.

P. Neven, M. Christiaens, F. Amant, 2014, Breast.

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.

P. Neven, C. Barrios, G. Jerusalem, 2015, Cancer treatment reviews.

Low 25-hydroxyvitamin d3 serum levels are associated with larger breast tumor size

P. Neven, D. Lambrechts, R. Paridaens, 2011 .

Genetic variation at CYP 3 A is associated with age at menarche and breast cancer risk : a case-control study

Jaana M. Hartikainen, S. Cross, M. Beckmann, 2014 .

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study

Patrick Neven, Chiun-Sheng Huang, Julian Peto, 2014, Breast Cancer Research.

BREAST CANCER PREVENTION: LIFESTYLE CHANGES AND CHEMOPREVENTION

P. Neven, J. Decloedt, S. Lambrechts, 2011, Acta clinica Belgica.

Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data

R. Vossen, S. Anvar, P. Neven, 2021, Science Translational Medicine.

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer

P. Neven, C. Desmedt, H. Wildiers, 2022, Scientific Reports.

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature

P. Neven, A. Wardley, M. Caira, 2020, Cancers.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

A. Giobbie-Hurder, J. Forbes, P. Neven, 2013, Breast Cancer Research and Treatment.

Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.

B. van Calster, V. Van Belle, P. Neven, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

S. Huffel, N. Pochet, D. Timmerman, 2008, Breast Cancer Research and Treatment.

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

P. Neven, A. Bardia, F. Esteva, 2021, British Journal of Cancer.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

P. Neven, R. Bose, H. Rugo, 2021, Breast Cancer Research and Treatment.

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

P. Neven, A. Jager, E. D. de Vries, 2020, Breast Cancer Research.

Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival

P. Neven, H. Wildiers, R. Dresen, 2019, Breast Cancer Research and Treatment.

Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer

P. Neven, D. Lambrechts, P. Moerman, 2019, Neoplasia.

Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions

Patrick Neven, Michael Jones, Julian Peto, 2014, Genetic epidemiology.

A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative.

P. Neven, E. Rakha, R. Paridaens, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

P. Neven, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of breast cancer

Patrick Neven, Jack Cuzick, Michael Baum, 1992, The Lancet.

Two truncating variants in FANCC and breast cancer risk

Jane E. Carpenter, M. Beckmann, P. Fasching, 2019, Scientific Reports.

Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency.

Patrick Neven, Diether Lambrechts, Annemieke Verstuyf, 2012, Carcinogenesis.

Body mass index and breast cancer survival: a Mendelian randomization analysis

Jaana M. Hartikainen, W. Willett, S. Cross, 2017, International journal of epidemiology.

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.

P. Fasching, P. Neven, X. Pivot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P. Neven, G. Sledge, P. Kaufman, 2018 .

Parent-of-Origin Specific Allelic Associations Among 106 Genomic Loci for Age at Menarche

Andrew D. Johnson, Daniel L. Koller, E. Demerath, 2014 .

Breast Cancer Guidelines Expert Panel

P. Neven, R. Scholten, M. Christiaens, 2013 .

Endometrial cancer

Patrick Neven, Dirk Timmerman, Philippe Moerman, 2005, The Lancet.

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

B. Moor, N. Pochet, D. Timmerman, 2007, Breast Cancer Research and Treatment.

11q13 is a susceptibility locus for hormone receptor positive breast cancer

Jaana M. Hartikainen, S. Cross, R. Schulz-Wendtland, 2012, Human mutation.

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape

P. Neven, H. Wildiers, K. Punie, 2021, ESMO open.

Robotic retroperitoneal lower para‐aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients

P. Neven, I. Vergote, F. Amant, 2008, Acta obstetricia et gynecologica Scandinavica.

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYL

P. Neven, H. Rugo, Yeon-Hee Park, 2020 .

BREAST CANCER IN WOMEN: DIAGNOSIS, TREATMENT AND FOLLOW-UP

P. Neven, R. Scholten, H. Wildiers, 2013 .

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

Patrick Neven, Peter Van Loo, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase inhibitors in the breast cancer clinic: focus on exemestane.

P. Neven, R. Paridaens, H. Wildiers, 2014, Endocrine-Related Cancer.

Ribociclib plus fulvestrant in the treatment of breast cancer

P. Neven, G. Jerusalem, G. Sonke, 2020, Expert review of anticancer therapy.

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.

P. Neven, A. Jager, E. Dees, 2021 .

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

H. Linden, P. Neven, S. Chandarlapaty, 2021 .

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198

P. Neven, R. Gelber, B. Gusterson, 2007 .

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

P. Neven, S. Loi, C. Swanton, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

B. van Calster, P. Neven, F. Amant, 2009, British Journal of Cancer.

Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers.

E. van Limbergen, P. Neven, R. Paridaens, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1

V. Van Belle, P. Neven, V. Belle, 2009, Journal of Clinical Pathology.

Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

P. Neven, I. Vergote, F. Amant, 2009, International Journal of Gynecologic Cancer.

Treatment modalities in endometrial cancer

E. van Limbergen, D. Timmerman, P. Neven, 2007, Current opinion in oncology.

Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006.

P. Neven, I. Vergote, F. Amant, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data

T. Speed, C. Sotiriou, P. Neven, 2014, Genome Biology.

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†

P. Neven, M. Campone, D. Hayes, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant trastuzumab in HER2-positive breast cancer.

P. Neven, R. Paridaens, J. Vanderhaegen, 2012, The New England journal of medicine.

Activity of fulvestrant in HER2-overexpressing advanced breast cancer.

S. Barni, P. Neven, J. Robertson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of fulvestrant in HER 2-overexpressing advanced breast cancer

S. Barni, P. Neven, J. Robertson, 2010 .

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

S. Huffel, D. Timmerman, P. Neven, 2008, Breast Cancer Research and Treatment.

Wilms' tumor gene 1 (WT1) in endometrial carcinoma.

P. Neven, F. Amant, A. Coosemans, 2008, Gynecologic oncology.

Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.

P. Neven, I. Vergote, H. Brems, 2020, Gynecologic oncology.

Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients

S. Huffel, P. Neven, M. Christiaens, 2011, Breast Cancer Research and Treatment.

Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I–II Cervical Cancer

P. Neven, F. Amant, P. Moerman, 2017, International Journal of Gynecologic Cancer.

Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors

B. van Calster, D. Timmerman, P. Neven, 2019, International Journal of Gynecological Cancer.

Biological ageing and frailty markers in breast cancer patients

P. Neven, H. Wildiers, A. Smeets, 2015, Aging.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, L. Chow, P. Goss, 2014, The oncologist.

Is the sentinel lymph node biopsy more sensitive for the identification of positive lymph nodes in breast cancer than the axillary lymph node dissection?

P. Neven, R. Paridaens, M. Christiaens, 2013, SpringerPlus.

Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor

P. Neven, F. Amant, A. Cornelis, 2008, Breast Care.

I.2 From the breast to the uterus. The past and the present

P. Neven, R. Campo, X. Muylder, 1998 .

Lasofoxifene in postmenopausal women with osteoporosis.

A. LaCroix, S. Cummings, T. Powles, 2010, The New England journal of medicine.

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial

P. Neven, H. Wildiers, H. Joensuu, 2018, JAMA oncology.

Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial

P. Neven, M. Christiaens, A. Smeets, 2011, BMJ : British Medical Journal.

The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer

P. Neven, H. Wildiers, K. Punie, 2015, Current Treatment Options in Oncology.

Pan-cancer detection and typing by mining patterns in large genome-wide cell-free DNA sequencing datasets

C. Dooms, D. Timmerman, P. Neven, 2022, medRxiv.

Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

P. Neven, F. Amant, I. Vergote, 2012, International Journal of Gynecologic Cancer.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

A. Giobbie-Hurder, J. Forbes, P. Neven, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

J. Forbes, P. Neven, C. Barrios, 2013 .

Everolimus in acute kidney injury in a patient with breast cancer: a case report

P. Neven, P. Wolter, D. Kuypers, 2014, Journal of Medical Case Reports.

264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)

H. Linden, P. Neven, S. Chandarlapaty, 2021, Annals of Oncology.

Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection

P. Neven, A. Jager, M. Cristofanilli, 2021 .

Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.

P. Neven, G. Hortobagyi, A. Bardia, 2020 .

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3

P. Neven, X. Pivot, G. Jerusalem, 2018, Geburtshilfe und Frauenheilkunde.

Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study

S. Cross, M. Beckmann, P. Fasching, 2017, Breast Cancer Research.

Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

P. Neven, H. Wildiers, H. Joensuu, 2018 .

Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC.

P. Neven, C. Desmedt, H. Wildiers, 2021 .

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis.

Jeffery M. Meyer, Jack A. Taylor, A. Whittemore, 2018, International journal of epidemiology.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

P. Neven, L. Plouffe, C. Arnaud, 2003, Menopause.

Body mass index and breast cancer survival: a Mendelian randomization analysis

W. Willett, S. Cross, P. Fasching, 2017, International Journal of Epidemiology.

Body mass index and breast cancer survival

S. Cross, P. Fasching, Jingmei Li, 2017 .

Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer

M. Beckmann, P. Fasching, Jingmei Li, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers

P. Neven, C. Van Ongeval, F. De Keyzer, 2021, European Journal of Radiology.

Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry

A. Whittemore, S. Cross, M. Beckmann, 2016, Cancer Causes & Control.

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

S. Cross, M. Lux, A. Olshan, 2023, Research square.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

C. Sotiriou, P. Neven, S. Loi, 2015, BMC Medicine.

Modulation of endometrial transforming growth factor β (TGFβ) by tamoxifen

P. Neven, P. Carmichael, J. Pole, 2000 .

The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.

S. Barni, P. Neven, R. Kreienberg, 2014, Breast.

A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients.

P. Neven, F. Rademakers, J. Voigt, 2008, Critical reviews in oncology/hematology.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?

P. Neven, M. Christiaens, I. Vergote, 2008, Breast Cancer Research and Treatment.

Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer

P. Neven, H. Wildiers, G. Floris, 2020, Breast Cancer Research and Treatment.

Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy

P. Neven, C. Desmedt, H. Wildiers, 2019, Breast Cancer Research and Treatment.

Risk group detection and survival function estimation for interval coded survival methods

Stephen P. Boyd, J. Suykens, S. Huffel, 2013, Neurocomputing.

Pain characteristics as important contributing factors to upper limb dysfunctions in breast cancer survivors at long term.

P. Neven, M. Christiaens, M. Meeus, 2017, Musculoskeletal science & practice.

PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.

B. van Calster, D. Timmerman, P. Neven, 2013, Gynecologic oncology.

Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.

P. Neven, J. Schellens, J. Severens, 2014, European journal of cancer care.

Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer

P. Neven, H. Wildiers, E. Dejaeger, 2022, Breast Cancer Research and Treatment.

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

P. Neven, S. Simoens, I. Huys, 2019, British Journal of Cancer.

Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2− early breast cancer

P. Neven, H. Wildiers, C. Van Ongeval, 2021, Modern Pathology.

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors

P. Neven, D. Lambrechts, R. Paridaens, 2014, BMC Cancer.

Abstract P3-10-05: Triple Negative Breast Cancer: Clinical Characteristics in the Different Histological Subtypes

P. Neven, R. Paridaens, H. Wildiers, 2010 .

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

P. Neven, F. André, G. Jerusalem, 2015, BMC Cancer.

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

P. Neven, G. von Minckwitz, H. Eidtmann, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The immunocytochemical versus cytosol measurement of the oestrogen receptor in invasive breast cancer tissue.

P. Neven, Y. van Belle, R. Tonglet, 2000, European journal of cancer.

Correlation Between Clinical Assessment and Lymphofluoroscopy in Patients with Breast Cancer-Related Lymphedema: A Study of Concurrent Validity.

P. Neven, I. Nevelsteen, I. Fourneau, 2020, Lymphatic research and biology.

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

P. Neven, B. Bekele, S. Eckert, 2002, Gynecologic oncology.

Is it safe to treat endometrial carcinoma endoscopically?

P. Neven, I. Vergote, F. Amant, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early drain removal improves quality of life and clinical outcomes in patients with breast cancer - Results from a randomised controlled trial.

P. Neven, A. Smeets, A. Laenen, 2018, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Effectiveness of postoperative physical therapy for upper-limb impairments after breast cancer treatment: a systematic review.

Patrick Neven, Inge Geraerts, P. Neven, 2015, Archives of physical medicine and rehabilitation.

An evaluation tool for myofascial adhesions in patients after breast cancer (MAP-BC evaluation tool): Development and interrater reliability

P. Neven, M. Christiaens, M. Van Kampen, 2017, PloS one.

Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors

P. Neven, O. Ortmann, P. Grob, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen

P. Neven, R. Mathijssen, M. Joerger, 2020, Frontiers in Pharmacology.

Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials

P. Neven, A. Bardia, L. Hart, 2019, Poster Session Abstracts.

Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade

P. Neven, J. Staessen, L. Thijs, 2023, Journal of the American Heart Association.

Tamoxifen or Aromatase Inhibitors in Breast Cancer: Efficacy and Safety

P. Neven, R. Broecke, 2007, Acta chirurgica Belgica.

Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations

P. Neven, D. Lambrechts, H. Wildiers, 2018, Breast Cancer Research and Treatment.

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

S. Cummings, T. Powles, P. Neven, 2012, Breast Cancer Research and Treatment.

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

P. Neven, H. Wildiers, G. Floris, 2016, British Journal of Cancer.

Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations.

P. Neven, J. Vermeesch, H. Wildiers, 2020, Clinical chemistry.

I.3 An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis?

P. Neven, P. Carmichael, J. Mills, 1998 .

The footprint of the ageing stroma in older patients with breast cancer

C. Sotiriou, P. Neven, D. Lambrechts, 2017, Breast Cancer Research.

Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.

P. Neven, C. Desmedt, H. Wildiers, 2023, European journal of cancer.

Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.

P. Neven, M. Christiaens, C. Van Ongeval, 2015, Breast.

Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer

P. Neven, M. Christiaens, H. Wildiers, 2013, SpringerPlus.

Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice.

P. Neven, R. Paridaens, M. Christiaens, 2013, Breast.

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

P. Neven, F. Esteva, X. Pivot, 2019, Annals of Oncology.

Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival.

P. Neven, H. Wildiers, G. Floris, 2018, Journal of geriatric oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) +/- trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data

P. Neven, R. Paridaens, H. Wildiers, 2006 .

Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer

P. Neven, H. Wildiers, G. Floris, 2021, Cancers.

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy

P. Neven, G. Pruneri, S. Loibl, 2018, Breast Cancer Research and Treatment.

Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.

P. Neven, F. Amant, K. Leunen, 2013, Gynecologic oncology.

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

P. Neven, Y. Hotko, H. Denys, 2023, Cancer Research.

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

P. Neven, A. Bardia, F. Bidard, 2023, Cancer Research.

Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

P. Neven, H. Rugo, Yeon-Hee Park, 2022, Cancer Research.

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

E. van Limbergen, A. Giobbie-Hurder, B. van Calster, 2018, The oncologist.

Other selective oestrogen receptor modulators (SERMs) in development.

P. Neven, 2000, European journal of cancer.

The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in ≥70-year-old early-stage invasive breast cancer patients.

P. Neven, C. Quinten, H. Wildiers, 2020, European journal of cancer care.

Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

P. Neven, I. Vergote, T. Juhler-Nøttrup, 2016 .

Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study.

P. Neven, S. Sunaert, P. Kuppens, 2020, Cancer.

Sequential Intra-arterial Infusion of 90Y-resin Microspheres and Mitomycin C in Chemo Refractory Liver Metastatic Breast Cancer Patients: a Single Centre Pilot Study

P. Neven, H. Wildiers, R. Dresen, 2020, Radiology and oncology.

The footprint of the ageing stroma in older patients with breast cancer

C. Sotiriou, P. Neven, D. Lambrechts, 2017, Breast Cancer Research.

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

A. Witteveen, A. Glas, L. Delahaye, 2019, Translational oncology.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, P. Goss, Bing-he Xu, 2014, The oncologist.

P. Neven, G. Viale, M. Regan, 2007 .

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

P. Neven, S. Loi, S. Nik-Zainal, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy

P. Neven, K. Marchal, M. Christiaens, 2008, Oncogene.

P. Neven, H. Wildiers, A. Smeets, 2018, BMC Cancer.

A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer

P. Neven, N. Harbeck, C. Kaiser, 2007, Clinical Cancer Research.

Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation

P. Neven, L. Plouffe, S. Goldstein, 2001, Obstetrics and gynecology.

Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.

P. Neven, R. Paridaens, M. Christiaens, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

P. Neven, H. Wildiers, A. Smeets, 2018, BMC Cancer.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

P. Neven, Chiun-Sheng Huang, H. Rugo, 2022, The Lancet. Oncology.

The validity and reliability of real-time ultrasound estimation of bladder volume in postnatal women

P. Neven, S. Ogston, P. Chien, 1996 .

Prospective study of uterine sonographic changes after 3 months endocrine treatment in postmenopausal breast cancer patients: tamoxifen is estrogenic while aromatase inhibitors induce atrophy and can reverse the effect of tamoxifen

S. Huffel, D. Timmerman, P. Neven, 2003 .

S1-3: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST.

P. Neven, H. Eidtmann, R. Coleman, 2011 .

Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors

S. Huffel, D. Timmerman, P. Neven, 2004 .

Endometrial changes in patients on tamoxifen.

P. Neven, 1995, Lancet.

Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer.

P. Neven, R. Van den Broecke, W. Poppe, 2009, Fertility and sterility.

The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer.

P. Neven, A. Bottomley, C. Quinten, 2017, Journal of geriatric oncology.

Prospective study on the effect of endocrine treatments on menopausal symptoms in breast cancer patients

S. Huffel, D. Timmerman, P. Neven, 2003 .

Prevalence of HIV antibody and pregnancy in Tayside, 1984-9: background to screening.

P. Neven, P. Howie, N. Patel, 1990, BMJ.

Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.

P. Neven, P. V. van Dam, M. Christiaens, 2014, Breast.

Relationship between age and axillary lymph node involvement in women with breast cancer.

B. van Calster, P. Neven, S. Van Huffel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are gene signatures better than traditional clinical factors?

V. Van Belle, P. Neven, R. Paridaens, 2008, The Lancet. Oncology.

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?

P. Neven, C. Desmedt, H. Wildiers, 2023, Annals of translational medicine.

Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial.

P. Neven, M. Christiaens, I. Vergote, 2018, Journal of physiotherapy.

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.

Hong Wang, P. Neven, A. Llombart-Cussac, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inter-rater reliability of shoulder measurements in middle-aged women.

P. Neven, M. Christiaens, F. Struyf, 2017, Physiotherapy.

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2

P. Neven, M. Karuturi, L. Schwartzberg, 2021, Breast.

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer

P. Neven, H. Wildiers, I. Vergote, 2018, Breast Cancer Research and Treatment.

Neoadjuvant chemotherapy for ovarian cancer.

P. Neven, I. Vergote, F. Amant, 2005, Oncology.

Reproducibility of lymphoscintigraphic evaluation of the upper limb.

P. Neven, M. Christiaens, I. Vergote, 2014, Lymphatic research and biology.

Obesity alters endoxifen plasma levels in young breast cancer patients: A pharmacometric simulation approach.

W. Huisinga, P. Neven, H. Brauch, 2020, Clinical pharmacology and therapeutics.

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer

P. Neven, D. Lambrechts, I. Vergote, 2020 .

Numb chin syndrome as a sign of mandibular metastasis: A case report

P. Neven, C. Politis, E. Hauben, 2017, International journal of surgery case reports.

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

P. Neven, H. Wildiers, G. Pawelec, 2017, Breast Cancer Research.

'Fracture incidence after 3 years of aromatase inhibitor therapy'.

P. Neven, D. Vanderschueren, M. Laurent, 2014, Annals of Oncology.

Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis.

P. Neven, R. Paridaens, M. Christiaens, 2009 .

Reconstruction of the abdominal wall with a latissimus dorsi musculocutaneous flap: a case of a massive abdominal wall metastasis from a cervical cancer requiring palliative resection.

P. Neven, J. Shepherd, K. Tham, 1993, Gynecologic oncology.

P. Neven, M. Piccart, G. Hortobagyi, 2013, Current medical research and opinion.

Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study)

P. Neven, A. Monnier, R. Coleman, 2006 .

P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer

P. Neven, A. Monnier, N. Bundred, 2005 .

Effect of myofascial techniques for treatment of upper limb dysfunctions in breast cancer survivors: randomized controlled trial

P. Neven, M. Christiaens, M. Van Kampen, 2017, Supportive Care in Cancer.

Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

J. Bergh, P. Neven, J. Cortes, 2019, Poster Session Abstracts.

P5-16-02: The Impact of Educational Materials on Compliance and Persistence with Adjuvant Aromatase Inhibitors: 2 Year Follow-Up and Final Results from the CARIATIDE Study.

P. Neven, R. Kreienberg, M. Tanner, 2011 .

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.

P. Neven, D. Lambrechts, I. Vergote, 2019, Journal of Clinical Oncology.

Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data

P. Neven, H. Wildiers, E. de Azambuja, 2023, Clinical epidemiology.

Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

P. Neven, E. Dees, J. E. Boers, 2019, Annals of Oncology.

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

P. Neven, G. Sledge, X. Pivot, 2019, Annals of Oncology.

Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation

P. Neven, F. Amant, V. Borges, 2021, International Journal of Gynecological Cancer.

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer

P. Neven, E. Tokunaga, Chiun-Sheng Huang, 2023, Therapeutic advances in medical oncology.

Clinical Significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant.

P. Neven, Hong Wang, G. Sledge, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer.

H. Putter, P. Neven, H. Guchelaar, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study.

P. Neven, H. Wildiers, C. Van Ongeval, 2023, Clinical breast cancer.

Why should results from metastatic trials no longer matter for early-stage disease?

P. Neven, D. Lambrechts, H. Wildiers, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

29PA NEGATIVE PROGESTERONE RECEPTOR IN LUMINAL HER-2 NEGATIVE BREAST CANCER BY AGE AT DIAGNOSIS: 10 YEARS FOLLOW-UP

P. Neven, M. Christiaens, H. Wildiers, 2014 .

Wilms’ tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours

P. Neven, F. Amant, L. Moons, 2009, Histopathology.

The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.

P. Neven, H. Eidtmann, R. Coleman, 2009 .

Abstract 4458: Clinical significance ofPIK3CAandESR1mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant

P. Neven, G. Sledge, A. Llombart-Cussac, 2019, Clinical Research (Excluding Clinical Trials).

Quasiclassical theory of disordered multi-channel Majorana quantum wires

P. Neven, A. Altland, D. Bagrets, 2013, 1302.0747.

The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.

P. Neven, F. Amant, T. Van Gorp, 2006, Minerva ginecologica.

MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

P. Neven, G. Sledge, X. Pivot, 2017 .

Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers.

E. van Limbergen, P. Neven, E. Kellen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

P. Neven, H. Rugo, L. Hart, 2023, Breast Cancer Research.

Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.

P. Neven, C. Desmedt, D. Larsimont, 2023, European journal of cancer.

P3-14-22: Response to Neoadjuvant Chemotherapy in Elderly Patients with Locally Advanced Breast Cancer.

P. Neven, R. Paridaens, M. Christiaens, 2011 .

Transition of endometrial stromal sarcoma into high-grade sarcoma.

P. Neven, I. Vergote, F. Amant, 2006, Gynecologic oncology.

Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.

N. Pochet, P. Neven, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Additional Value of PET–CT in Staging of Clinical Stage IIB and III Breast Cancer

P. Neven, F. Mottaghy, R. Paridaens, 2010, The breast journal.

ARandomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy forAdvanced Breast Cancer

P. Neven, N. Harbeck, C. Kaiser, 2007 .

TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES

P. Neven, J. Machiels, J. Canon, 2009, Acta clinica Belgica.

Reproduction rates after cytotoxic therapy.

P. Neven, R. Paridaens, H. Wildiers, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair

Andrew D. Johnson, E. Demerath, Toshiko Tanaka, 2015 .

Bmc Medical Genomics the Gene Expression Grade Index: a Potential Predictor of Relapse for Endocrine-treated Breast Cancer Patients in the Big 1–98 Trial

A. Giobbie-Hurder, C. Sotiriou, P. Neven, 2022 .

A technical guideline: collection of adequate PAP smears of the uterine cervix

P. Neven, F. Buntinx, P. Dam, 2001 .

Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study

P. Neven, I. Vergote, A. Wolthuis, 2023, Annals of medicine and surgery.

Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters?

P. Neven, A. Soubry, Stephanie Romanus, 2016, Breast Cancer Research.

Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled

P. Neven, A. Musolino, K. Blackwell, 2013 .

Prospective external validation of the ‘ovarian crescent sign’ as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology

T. Bourne, D. Timmerman, P. Neven, 2010, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

VI.6 Detection of DNA adducts in the human endometrium: a lack of evidence

T. Bourne, P. Neven, D. Phillips, 1998 .

II.2 Tamoxifen and benign endometrial lesions

P. Neven, Y. Belle, X. D. Muylder, 1998 .

The Gene Expression Grade Index: A Potential Predictor of Relapse for Endocrine-treated Breast Cancer Patients in the BIG 1–98 Trial

A. Giobbie-Hurder, C. Sotiriou, P. Neven, 2022 .

Tamoxifen-induced endometrial polyp.

P. Neven, Y. van Belle, X. De Muylder, 1997, The New England journal of medicine.

Tamoidfen: the need for a monitoring protocol

P. Neven, 1996 .

Treatment of cancer during pregnancy: the need for tailored strategies

P. Neven, F. Amant, K. Calsteren, 2010 .

Who needs adjuvant systemic treatment ? Predicting prognosis in node-negative breast cancer ; from bench to bedside

P. Neven, V. Belle, M. Christiaens, 2009 .

Adverse events with everolimus in BOLERO-2.

P. Neven, H. Wildiers, P. Wolter, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors

P. Neven, C. Desmedt, D. Lambrechts, 2023, Cancers.

Obesity-associated changes in molecular biology of primary breast cancer

M. J. van de Vijver, A. Witteveen, A. Glas, 2023, Nature communications.

Importance of synovial fluid retention and tickening in patients with severe musculoskeletal pain treated with letrozole or exemstance: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging

D. Timmerman, P. Neven, R. Paridaens, 2006 .

Biology and prognosis by age of primary operable breast cancer.

Patrick Neven, S. Van Huffel, Frédéric Amant, 2009 .

Circulating estradiol and tumor phenotype in postmenopausal breast cancer patients.

P. Neven, Hyonil Cho, 2009, Maturitas.

Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome.

P. Neven, D. Lambrechts, M. Schmidt, 2021, European Journal of Cancer.

Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting

P. Neven, R. Paridaens, L. Morales, 2005, Current opinion in oncology.

Abstract P6-07-19: Prognostic relevance of PR and detection mode in Luminal Her-2 negative breast cancer

P. Neven, R. Paridaens, M. Christiaens, 2012 .

Abstract P6-08-03: Germline mutational landscape in 5422 individuals at risk for hereditary breast and ovarian cancer who underwent multi-gene panel testing

H. Peeters, P. Neven, C. Desmedt, 2020 .

Risk-reducing mastectomy in BRCA carriers: survival is not the issue

P. Neven, H. Wildiers, C. Van Ongeval, 2019, Breast Cancer Research and Treatment.

Serum methylmalonic acid concentrations at breast cancer diagnosis significantly correlate with clinical frailty

P. Neven, C. Desmedt, H. Wildiers, 2023, GeroScience.

Reply to A.C. Voogd et al

P. Neven, M. Christiaens, H. Wildiers, 2009 .

Lymph node ratio better predicts disease-free survival in node-positive breast cancer than the number of positive lymph nodes.

V. Van Belle, P. Neven, S. Van Huffel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers.

E. van Limbergen, P. Neven, E. Kellen, 2013 .

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

P. Neven, D. Yee, K. Blackwell, 2011 .

Parent-of-origin specific allelic associations among 106 genomic loci for age at menarche

John P. Rice, Daniel L. Koller, D. J. Thompson, 2014, Nature.

Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology

D. Timmerman, P. Neven, R. Paridaens, 2006, Clinical Cancer Research.

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features

P. Neven, A. Broeks, D. Lambrechts, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

P. Neven, P. Benedetti‐Panici, T. Nickelsen, 2003, BJOG : an international journal of obstetrics and gynaecology.

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

P. Neven, G. von Minckwitz, A. Monnier, 2008, Cancer.

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.

P. Neven, D. Lambrechts, I. Vergote, 2023, European journal of cancer.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Kristen S Purrington, Jack A. Taylor, A. Whittemore, 2018, American Journal of Human Genetics.

Extended adjuvant letrozole following five years of tamoxifen is cost-effective from a Belgian health care payer's perspective

P. Neven, R. Paridaens, L. Dirix, 2006 .

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

R. Schiff, P. Neven, J. Mackey, 2011, Clinical Cancer Research.

Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.

A. Giobbie-Hurder, E. Winer, J. Forbes, 2013 .

Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

P. Neven, I. Vergote, F. Amant, 2009, International Journal of Gynecologic Cancer.

Effect of tamoxifen on bone.

P. Neven, X. De Muylder, 1993, BMJ.

Radical vulvectomy using the argon enhanced electro‐surgical pencil

P. Neven, D. Wilkinson, J. Shepherd, 1993, British journal of obstetrics and gynaecology.

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

P. Neven, F. Amant, B. Calster, 2007, British Journal of Cancer.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

P. Neven, M. Piccart, G. Hortobagyi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.

P. Neven, A. Bardia, L. Hart, 2022, Journal of Clinical Oncology.

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

P. Neven, M. Campone, D. Hayes, 2014 .

Aromatase inhibitors in the breast cancer clinic: focus on exemestane.

P. Neven, R. Paridaens, H. Wildiers, 2014, Endocrine-related cancer.

Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor

P. Neven, R. Paridaens, H. Wildiers, 2011, Menopause.

Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review

P. Neven, H. Wildiers, J. Detraux, 2016, Acta psychiatrica Scandinavica.

THE POSITIVE ASSOCIATION BETWEEN BREAST TUMOR SIZE AND LYMPH NODE INVOLVEMENT IN LOBULAR BREAST CANCERS IS PROGESTERONE RECEPTOR DEPENDENT

P. Neven, R. Paridaens, H. Wildiers, 2010 .

Lymphadenectomy in endometrial cancer

P. Neven, I. Vergote, F. Amant, 2009, The Lancet.

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences

P. Neven, M. Gnant, D. Cameron, 2023, JNCI cancer spectrum.

The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.

D. Timmerman, P. Neven, D. Lambrechts, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy: an Analysis of 74 Patients With Advanced Epithelial Ovarian Cancer

P. Neven, F. Amant, D. Tsolakidis, 2010, International Journal of Gynecologic Cancer.

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

Jaana M. Hartikainen, Sandra L. Halverson, A. Whittemore, 2015, Nature Genetics.

Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)

P. Neven, D. Lambrechts, I. Vergote, 2022, Gynecologic Oncology.

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

P. Neven, G. Sledge, H. Rugo, 2021, Breast cancer research : BCR.

Reproduction rates after cytotoxic therapy.

P. Neven, R. Paridaens, H. Wildiers, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone receptor expression in Flemish patients with in situ and invasive primary breast cancer

P. Neven, P. Dam, W. Tjalma, 2002 .

Biological ageing and frailty markers in breast cancer patients

P. Neven, H. Wildiers, A. Smeets, 2015, Aging.

Reply to H.A. Azim Jr et al

P. Neven, F. Amant, K. Calsteren, 2010 .

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven, C. Wang, G. Jerusalem, 2023, Breast Cancer Research.

Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy

P. Neven, 1990, British journal of obstetrics and gynaecology.

Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.

P. Neven, R. Paridaens, M. Christiaens, 2014, European journal of cancer.

An evaluation tool for Myofascial Adhesions in Patients after Breast Cancer (MAP-BC evaluation tool): Concurrent, face and content validity

P. Neven, M. Christiaens, E. Van den kerckhove, 2018, PloS one.

Magnetic Seed Localisation for Non-Palpable Breast Lesions: A Comparison with Hooked-Wire

P. Neven, A. Smeets, A. Laenen, 2021, Austin Journal of Medical Oncology.

Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy.

E. van Limbergen, P. Neven, S. Peeters, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.

Fertility preservation in (breast) cancer patients: is it safe?

P. Neven, R. Paridaens, H. Wildiers, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.